Dataset Information

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.

ABSTRACT: Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management.

SUBMITTER: Talasaz AH

PROVIDER: S-EPMC8504484 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.

Talasaz Azita H AH Sadeghipour Parham P Aghakouchakzadeh Maryam M Dreyfus Isaac I Kakavand Hessam H Ariannejad Hamid H Gupta Aakriti A Madhavan Mahesh V MV Van Tassell Benjamin W BW Jimenez David D Monreal Manuel M Vaduganathan Muthiah M Fanikos John J Dixon Dave L DL Piazza Gregory G Parikh Sahil A SA Bhatt Deepak L DL Lip Gregory Y H GYH Stone Gregg W GW Krumholz Harlan M HM Libby Peter P Goldhaber Samuel Z SZ Bikdeli Behnood B

Journal of the American College of Cardiology 20211001 16

Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a s ...[more]

PMID: 34649702

Dataset Information

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.

Publications

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.
| S-EPMC7164881 | biostudies-literature

Transcatheter Electrosurgery: JACC State-of-the-Art Review.
| S-EPMC7184929 | biostudies-literature

Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review.
| S-EPMC7535809 | biostudies-literature

Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review.
| S-EPMC6538508 | biostudies-literature

Medial Arterial Calcification: JACC State-of-the-Art Review.
| S-EPMC8439554 | biostudies-literature

Cardiac Tumors: <i>JACC CardioOncology</i> State-of-the-Art Review.
| S-EPMC8352246 | biostudies-literature

Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review.
| S-EPMC7058348 | biostudies-literature

Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: <i>JACC CardioOncology</i> State-of-the-Art Review.
| S-EPMC8352294 | biostudies-literature

Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review.
| S-EPMC9941752 | biostudies-literature

Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review.
| S-EPMC7808240 | biostudies-literature